P2110mg
P21 Canada — 10 mg Lyophilized Vials
Neurotrophic Peptide Mimetic
Also known as P021 / CNTF-derived peptidergic compound
P21 is a small peptidergic compound derived from an active region of ciliary neurotrophic factor (CNTF), studied in research for neurogenic and synaptogenic signaling. Supplied strictly for laboratory research use within Canada. Not for human or veterinary use.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off vials.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
P21 is a small peptidergic compound derived from an active region of ciliary neurotrophic factor (CNTF), studied in research for neurogenic and synaptogenic signaling.
Experimental models examine its effect on hippocampal neurogenesis, BDNF expression and synaptic plasticity endpoints.
P21 (P021) was developed from an active fragment of ciliary neurotrophic factor and chemically modified to improve stability and brain penetration relative to the parent peptide. That modification is what allows it to be dosed in whole-animal work rather than only in cell culture.
Research frameworks use it to probe neurotrophic signaling: adult hippocampal neurogenesis in the dentate gyrus, BDNF-associated pathways, dendritic and synaptic markers, and tau-related endpoints in aged and transgenic rodent models.
Neurotrophic factors such as CNTF showed activity in neurodegeneration models but were poor drug candidates — large, unstable, and unable to cross the blood-brain barrier in useful amounts. That motivated a search for small-molecule and peptide mimetics reproducing the signaling without the delivery problem.
P021 emerged from that work as an adamantylated tetrapeptide derived from a CNTF active region. It was subsequently characterized in a triple-transgenic Alzheimer model, in aged rats where cerebrospinal-fluid tau was measured, and in the Ts65Dn mouse model of Down syndrome, including treatment initiated during early postnatal development.
Laboratory investigations into P21 focus on neurotrophic signaling and its structural correlates. Research frameworks evaluate adult hippocampal neurogenesis, BDNF expression and downstream plasticity pathways, dendritic and synaptic markers, and tau-related endpoints in transgenic and aged rodent models under controlled conditions.
2 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Kazim SF et al. 2014, Khatoon S et al. 2015, Kazim SF et al. 2017. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on adult, hippocampal or neurogenesis. This heading marks where P21 is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Addressed on this page by Kazim 2016. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on neurodevelopmental or rodent. This heading marks where P21 is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 4 primary papers published between 2014 and 2017 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Worth noting when weighing that record: roughly 50% of the citations here list Kazim SF et al. as lead author. A literature concentrated in one research group has not been independently replicated to the same degree as one drawn from many, and that is a real limitation on how far the findings can be generalised — regardless of how consistent the individual results look.
P21 is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for P21, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
P21 is commonly described online in connection with sharper focus, better memory and improved mood. In the research literature the same compound is filed under CNTF-derived neurotrophic signaling models, adult hippocampal neurogenesis research and synaptic plasticity and BDNF pathway studies.
The 4 papers cited on this page, published between 2014 and 2017 (3 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Presented as having independent scientific backing.
Around 50% of the papers cited here list Kazim SF et al. as lead author. A literature concentrated in one research group has not been independently replicated to the degree its volume suggests, and that is a real limit on how far the findings generalise — however consistent the individual results appear.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for P21 is per lot, not per product. The current 10mg lot P21-CA-26H-10 returned 99.339% purity, 12.24 mg measured, 122.4% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is P21; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for P21, this lot measured 122.4% of its labelled 10 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for P21. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy P21 in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
P21 is supplied as lyophilized powder. It is not a peptide, and solvent behaviour follows from its own chemistry rather than from the aqueous-vehicle conventions that apply to peptide material — the published literature for this compound is the reference for solvent selection, not a general peptide protocol.
Dry storage below freezing and protection from light are the general controls. As with any lyophilized material, the powder frequently sits as a thin film at the base of the vial and is easy to mistake for an empty vial before inspection.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of P21. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer’s disease
PubMedElevated Tau Level in Aged Rat Cerebrospinal Fluid Reduced by Treatment with a Neurotrophic Compound
PubMedEarly neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome
PubMedNeurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease
PubMedRelated
Peptides
Triple GIP / GLP-1 / Glucagon Agonist · 10, 20, 40 & 120 mg Retatrutide is a synthetic peptide developed for controlled laboratory research involving multi-receptor signaling systems. It is structurally designed to interact with GLP-1, GIP, and glucagon receptor pathways within experimental environments.
RETA-CA-26F-1099.637%
11.76 mg / 10 mg
$59.95CAD
Peptides
Dual GIP / GLP-1 Agonist · 10, 30 & 65 mg Tirzepatide is a synthetic peptide developed for controlled laboratory research involving dual incretin receptor signaling systems. It is structurally designed to interact with GLP-1 and GIP receptor pathways within experimental environments.
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$34.95CAD
Peptides
GLP-1 Receptor Agonist · 10 mg Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone involved in glucose-dependent signaling. It is developed for controlled laboratory investigation within regulated experimental environments.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$54.95CAD
Peptides
Selective Amylin Agonist (LY3841136) · 10 mg This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$144.95CAD
